Dernière mise à jour : 14 décembre 2012
Détails
FichiersGeneric Name:
Bendamustine hydrochloride
État du projet:
Terminé
Domaine thérapeutique:
Chronic Lymphocytic Leukemia (relapsed/refractory)
Fabricant:
Lundbeck Canada Inc.
Brand Name:
Treanda
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0011-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
25mg/vial and 100mg/vial
Tumour Type:
Leukemia
Indications:
chronic lymphocytic leukemia (CLL)
Funding Request:
Patients with Chronic Lymphocytic Leukemia (relapsed/refractory) for whom fludarabine-based therapy is not appropriate
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Ne pas rembourser
Clarification:
As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL was deferred to the January 17, 2013 pERC meeting date, once the submitter provided the requested additional economic information. Please see the Bendamustine (Treanda) for Chronic Lymphocytic Leukemia (First Line) Details page for more information.
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 14 décembre 2012